vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是Purple Innovation, Inc.的1.3倍（$183.1M vs $140.7M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -2.3%，领先15.6%），Purple Innovation, Inc.同比增速更快（9.1% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-7.8M），过去两年Purple Innovation, Inc.的营收复合增速更高（8.3% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
AMPH vs PRPL — 直观对比
营收规模更大
AMPH
是对方的1.3倍
$140.7M
营收增速更快
PRPL
高出10.9%
-1.8%
净利率更高
AMPH
高出15.6%
-2.3%
自由现金流更多
AMPH
多$32.4M
$-7.8M
两年增速更快
PRPL
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $140.7M |
| 净利润 | $24.4M | $-3.2M |
| 毛利率 | 46.8% | 41.9% |
| 营业利润率 | 19.4% | -1.6% |
| 净利率 | 13.3% | -2.3% |
| 营收同比 | -1.8% | 9.1% |
| 净利润同比 | -35.7% | 62.1% |
| 每股收益（稀释后） | $0.51 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHPRPL
| Q4 25 | $183.1M | $140.7M | ||
| Q3 25 | $191.8M | $118.8M | ||
| Q2 25 | $174.4M | $105.1M | ||
| Q1 25 | $170.5M | $104.2M | ||
| Q4 24 | $186.5M | $129.0M | ||
| Q3 24 | $191.2M | $118.6M | ||
| Q2 24 | $182.4M | $120.3M | ||
| Q1 24 | $171.8M | $120.0M |
净利润AMPHPRPL
| Q4 25 | $24.4M | $-3.2M | ||
| Q3 25 | $17.4M | $-11.7M | ||
| Q2 25 | $31.0M | $-17.3M | ||
| Q1 25 | $25.3M | $-19.1M | ||
| Q4 24 | $38.0M | $-8.5M | ||
| Q3 24 | $40.4M | $-39.2M | ||
| Q2 24 | $37.9M | $27.0K | ||
| Q1 24 | $43.2M | $-50.2M |
毛利率AMPHPRPL
| Q4 25 | 46.8% | 41.9% | ||
| Q3 25 | 51.4% | 42.8% | ||
| Q2 25 | 49.6% | 35.9% | ||
| Q1 25 | 50.0% | 39.4% | ||
| Q4 24 | 46.5% | 42.9% | ||
| Q3 24 | 53.3% | 29.7% | ||
| Q2 24 | 52.2% | 40.7% | ||
| Q1 24 | 52.4% | 34.8% |
营业利润率AMPHPRPL
| Q4 25 | 19.4% | -1.6% | ||
| Q3 25 | 13.2% | -10.2% | ||
| Q2 25 | 24.2% | -13.5% | ||
| Q1 25 | 21.9% | -13.9% | ||
| Q4 24 | 24.2% | -6.0% | ||
| Q3 24 | 29.8% | -39.5% | ||
| Q2 24 | 30.3% | -12.1% | ||
| Q1 24 | 27.9% | -19.3% |
净利率AMPHPRPL
| Q4 25 | 13.3% | -2.3% | ||
| Q3 25 | 9.0% | -9.9% | ||
| Q2 25 | 17.8% | -16.5% | ||
| Q1 25 | 14.8% | -18.4% | ||
| Q4 24 | 20.4% | -6.6% | ||
| Q3 24 | 21.1% | -33.1% | ||
| Q2 24 | 20.8% | 0.0% | ||
| Q1 24 | 25.1% | -41.8% |
每股收益（稀释后）AMPHPRPL
| Q4 25 | $0.51 | $0.03 | ||
| Q3 25 | $0.37 | $0.11 | ||
| Q2 25 | $0.64 | $0.16 | ||
| Q1 25 | $0.51 | $0.18 | ||
| Q4 24 | $0.74 | $0.08 | ||
| Q3 24 | $0.78 | $0.36 | ||
| Q2 24 | $0.73 | $0.00 | ||
| Q1 24 | $0.81 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $24.3M |
| 总债务越低越好 | $608.7M | $126.7M |
| 股东权益账面价值 | $788.8M | $-29.7M |
| 总资产 | $1.6B | $296.3M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHPRPL
| Q4 25 | $282.8M | $24.3M | ||
| Q3 25 | $276.2M | $32.4M | ||
| Q2 25 | $231.8M | $34.2M | ||
| Q1 25 | $236.9M | $21.6M | ||
| Q4 24 | $221.6M | $29.0M | ||
| Q3 24 | $250.5M | $23.4M | ||
| Q2 24 | $217.8M | $23.4M | ||
| Q1 24 | $289.6M | $34.5M |
总债务AMPHPRPL
| Q4 25 | $608.7M | $126.7M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $70.7M | ||
| Q3 24 | $596.4M | $50.8M | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHPRPL
| Q4 25 | $788.8M | $-29.7M | ||
| Q3 25 | $776.7M | $-26.9M | ||
| Q2 25 | $757.5M | $-15.6M | ||
| Q1 25 | $751.3M | $1.3M | ||
| Q4 24 | $732.3M | $20.2M | ||
| Q3 24 | $727.7M | $28.0M | ||
| Q2 24 | $713.3M | $66.4M | ||
| Q1 24 | $672.4M | $65.5M |
总资产AMPHPRPL
| Q4 25 | $1.6B | $296.3M | ||
| Q3 25 | $1.7B | $302.1M | ||
| Q2 25 | $1.6B | $303.8M | ||
| Q1 25 | $1.6B | $293.8M | ||
| Q4 24 | $1.6B | $307.8M | ||
| Q3 24 | $1.5B | $309.3M | ||
| Q2 24 | $1.5B | $362.1M | ||
| Q1 24 | $1.6B | $382.1M |
负债/权益比AMPHPRPL
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 3.50× | ||
| Q3 24 | 0.82× | 1.82× | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-7.8M |
| 自由现金流率自由现金流/营收 | 13.4% | -5.5% |
| 资本支出强度资本支出/营收 | 4.5% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $-41.9M |
8季度趋势，按日历期对齐
经营现金流AMPHPRPL
| Q4 25 | $32.9M | $-5.8M | ||
| Q3 25 | $52.6M | $-968.0K | ||
| Q2 25 | $35.6M | $-4.0M | ||
| Q1 25 | $35.1M | $-23.1M | ||
| Q4 24 | $29.0M | $6.8M | ||
| Q3 24 | $60.0M | $1.1M | ||
| Q2 24 | $69.1M | $-8.9M | ||
| Q1 24 | $55.3M | $-16.8M |
自由现金流AMPHPRPL
| Q4 25 | $24.6M | $-7.8M | ||
| Q3 25 | $47.2M | $-1.8M | ||
| Q2 25 | $25.0M | $-7.0M | ||
| Q1 25 | $24.4M | $-25.3M | ||
| Q4 24 | $16.6M | $5.7M | ||
| Q3 24 | $46.2M | $101.0K | ||
| Q2 24 | $63.1M | $-11.0M | ||
| Q1 24 | $46.5M | $-19.9M |
自由现金流率AMPHPRPL
| Q4 25 | 13.4% | -5.5% | ||
| Q3 25 | 24.6% | -1.5% | ||
| Q2 25 | 14.3% | -6.6% | ||
| Q1 25 | 14.3% | -24.3% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 0.1% | ||
| Q2 24 | 34.6% | -9.2% | ||
| Q1 24 | 27.1% | -16.5% |
资本支出强度AMPHPRPL
| Q4 25 | 4.5% | 1.4% | ||
| Q3 25 | 2.8% | 0.7% | ||
| Q2 25 | 6.1% | 2.8% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 0.8% | ||
| Q3 24 | 7.2% | 0.9% | ||
| Q2 24 | 3.3% | 1.7% | ||
| Q1 24 | 5.1% | 2.5% |
现金转化率AMPHPRPL
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | -330.22× | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
